2015•OncotargetOpen access

A new class of small molecule estrogen receptor-alpha antagonists that overcome anti-estrogen resistance

Yongxian Ma, Anju Preet, York A. Tomita, Eliseu De Oliveira, Li Zhang, Yumi Ueda, Robert C. Clarke, Milton L. Brown, Eliot M. Rosen

Open full text 4 citations

Abstract

// Yongxian Ma 1 , Anju Preet 1 , York Tomita 1,4 , Eliseu De Oliveira 1,4 , Li Zhang 1,4 ,Yumi Ueda 1 , Robert Clarke 1 , Milton Brown 1,4 and Eliot M. Rosen 1,2,3 1 Department of Oncology, Georgetown University School of Medicine, Washington, DC, USA 2 Department of Biochemistry and Molecular and Cellular Biology, Georgetown University School of Medicine, Washington, DC, USA 3 Department of Radiation Medicine, Georgetown University School of Medicine, Washington, DC, USA 4 Department of Center for Drug Discovery Georgetown University School of Medicine, Washington, DC, USA Correspondence to: Eliot M. Rosen, email: // Keywords : BRCA1, estrogen receptor (ER-α), antagonist, agonist, Tamoxifen Received : June 24, 2015 Accepted : October 01, 2015 Published : November 13, 2015 Abstract Previous studies indicate that BRCA1 protein binds to estrogen receptor-alpha (ER) and inhibits its activity. Here, we found that BRCA1 over-expression not only inhibits ER activity in anti-estrogen-resistant LCC9 cells but also partially restores their sensitivity to Tamoxifen. To simulate the mechanism of BRCA1 inhibition of ER in the setting of Tamoxifen resistance, we created a three-dimensional model of a BRCA1-binding cavity within the ER/Tamoxifen complex; and we screened a pharmacophore database to identify small molecules that could fit into this cavity. Among the top 40 “hits”, six exhibited potent ER inhibitory activity in anti-estrogen-sensitive MCF-7 cells and four of the six exhibited similar activity (IC 50 ≤ 1.0 μM) in LCC9 cells. We validated the model by mutation analysis. Two representative compounds (4631-P/1 and 35466-L/1) inhibited ER-dependent cell proliferation in Tamoxifen-resistant cells (LCC9 and LCC2) and partially restored sensitivity to Tamoxifen. The compounds also disrupted the association of BRCA1 with ER. In electrophoretic mobility shift assays, the compounds caused dissociation of ER from a model estrogen response element. Finally, a modified form of compound 35446 (hydrochloride salt) inhibited growth of LCC9 tumor xenografts at non-toxic concentrations. These results identify a novel group of small molecules that can overcome Tamoxifen resistance.

Open-access reader

About this research paper

What this paper is about

// Yongxian Ma 1 , Anju Preet 1 , York Tomita 1,4 , Eliseu De Oliveira 1,4 , Li Zhang 1,4 ,Yumi Ueda 1 , Robert Clarke 1 , Milton Brown 1,4 and Eliot M. Rosen 1,2,3 1 Department of Oncology, Georgetown University School of Medicine, Washington, DC, USA 2 Department of Biochemistry and Molecular and Cellular Biology, Georgetown University School of Medicine, Washington, DC, USA 3 Department of Radiation Medicine, Georgetown University School of Medicine, Washington, DC, USA 4 Department of Center for Drug Discovery Georgetown University School of Medicine, Washington, DC, USA Correspondence to: Eliot M. Rosen, email: // Keywords : BRCA1, estrogen receptor (ER-α), antagonist, agonist, Tamoxifen Received : June 24, 2015 Accepted : October 01, 2015 Published : November 13, 2015 Abstract Previous studies indicate that BRCA1 protein binds to estrogen receptor-alpha (ER) and inhibits its activity. Here, we found that BRCA1 over-expression not only inhibits ER activity in anti-estrogen-resistant LCC9 cells but also partially restores their sensitivity to Tamoxifen. To simulate the mechanism of BRCA1 inhibition of ER in the setting of Tamoxifen resistance, we created a three-dimensional model of a BRCA1-binding cavity within the ER/Tamoxifen complex; and we screened a pharmacophore database to identify small molecules that could fit into this cavity. Among the top 40 “hits”, six exhibited potent ER inhibitory activity in anti-estrogen-sensitive MCF-7 cells and four of the six exhibited similar activity (IC 50 ≤ 1.0 μM) in LCC9 cells. We validated the model by mutation analysis. Two representative compounds (4631-P/1 and 35466-L/1) inhibited ER-dependent cell proliferation in Tamoxifen-resistant cells (LCC9 and LCC2) and partially restored sensitivity to Tamoxifen. The compounds also disrupted the association of BRCA1 with ER. In electrophoretic mobility shift assays, the compounds caused dissociation of ER from a model estrogen response element. Finally, a modified form of compound 35446 (hydrochloride salt) inhibited growth of LCC9 tumor xenografts at non-toxic concentrations. These results identify a novel group of small molecules that can overcome Tamoxifen resistance.

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

// Yongxian Ma 1 , Anju Preet 1 , York Tomita 1,4 , Eliseu De Oliveira 1,4 , Li Zhang 1,4 ,Yumi Ueda 1 , Robert Clarke 1 , Milton Brown 1,4 and Eliot M. Rosen 1,2,3 1 Department of Oncology, Georgetown University School of Medicine, Washington, DC, USA 2 Department of Biochemistry and Molecular and Cellular Biology, Georgetown University School of Medicine, Washington, DC, USA 3 Department of Radiation Medicine, Georgetown University School of Medicine, Washington, DC, USA 4 Department of Center for Drug Discovery Georgetown University School of Medicine, Washington, DC, USA Correspondence to: Eliot M. Rosen, email: // Keywords : BRCA1, estrogen receptor (ER-α), antagonist, agonist, Tamoxifen Received : June 24, 2015 Accepted : October 01, 2015 Published : November 13, 2015 Abstract Previous studies indicate that BRCA1 protein binds to estrogen receptor-alpha (ER) and inhibits its activity. Here, we found that BRCA1 over-expression not only inhibits ER activity in anti-estrogen-resistant LCC9 cells but also partially restores their sensitivity to Tamoxifen. To simulate the mechanism of BRCA1 inhibition of ER in the setting of Tamoxifen resistance, we created a three-dimensional model of a BRCA1-binding cavity within the ER/Tamoxifen complex; and we screened a pharmacophore database to identify small molecules that could fit into this cavity. Among the top 40 “hits”, six exhibited potent ER inhibitory activity in anti-estrogen-sensitive MCF-7 cells and four of the six exhibited similar activity (IC 50 ≤ 1.0 μM) in LCC9 cells. We validated the model by mutation analysis. Two representative compounds (4631-P/1 and 35466-L/1) inhibited ER-dependent cell proliferation in Tamoxifen-resistant cells (LCC9 and LCC2) and partially restored sensitivity to Tamoxifen. The compounds also disrupted the association of BRCA1 with ER. In electrophoretic mobility shift assays, the compounds caused dissociation of ER from a model estrogen response element. Finally, a modified form of compound 35446 (hydrochloride salt) inhibited growth of LCC9 tumor xenografts at non-toxic concentrations. These results identify a novel group of small molecules that can overcome Tamoxifen resistance.

Key concepts: Estrogen, Estrogen receptor alpha, Estrogen receptor beta, Alpha (finance), Medicine, Estrogen receptor, Estrogen-related receptor alpha, Small molecule

Related papers

Back to paper searchBrowse research topicsOriginal source
A new class of small molecule estrogen receptor-alpha antagonists that overcome anti-estrogen resistance — Research Paper | ScholarLens